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Staphylococcus aureus is a common pathogen seen in prosthetic vascular graft, leading
to high morbidity andmortality. The virulence genes for severity of infections are under the
control of global regulators. Staphylococcal accessory regulator A (SarA) a knownmaster
controller of biofilm formation is an attractive target for the drug development. A structure
based screening of lead compounds was employed for the identification of novel small
molecule inhibitors targeted to interact to the DNA binding domain of the transcriptional
activator, SarA and hinder its response over the control of genes that up-regulate
the phenotype, biofilm. The top-hit SarA selective inhibitor, 4-[(2,4-diflurobenzyl)amino]
cyclohexanol (SarABI) was further validated in-vitro for its efficacy. The SarABI was
found to have MBIC50value of 200µg/ml and also down-regulated the expression of
the RNA effector, (RNAIII), Hemolysin (hld), and fibronectin-binding protein (fnbA). The
anti-adherence property of SarABI on S. aureus invasion to the host epithelial cell lines
(Hep-2) was examined where no significant attachment of S. aureus was observed. The
SarABI inhibits the colonization of MDR S. aureus in animal model experiment significantly
cohere to the molecular docking studies and in vitro experiments. So, we propose that
the SarABI could be a novel substitute to overcome a higher degree of MDR S. aureus
colonization on vascular graft.
Keywords: Staphylococcus aureus, multi drug resistance, SarA, quorum sensing, molecular docking, virulence
gene expression, vascular graft associated infection
Introduction
Staphylococcus aureus is the most commonly isolated pathogen in the prosthetic vascular graft
implanted in patients and uses a synchronized multiple virulence gene expression to establish
infection in humans (Legout et al., 2012) and leads to organ failure, and death particularly in
immunocompromised patients (Barnes and Chetter, 2012). The associated infections cause severe
clinical threat because of the greater morbidity and mortality related to its opportunistic behavior
(Lister and Horswill, 2014). S. aureus colonizes in prosthetic grafts to form a remarkable multilayer
biofilm that is very difficult to treat clinically since the bacterial cells within the biofilm are resistant
to the host immune response and antibiotic agents (Daghighi et al., 2013).
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Various pathways have been elucidated in S. aureus that are
linked with its pathogenicity and virulence gene expression.
The RNAIII is the intracellular effector of the agr quorum
sensing mechanism to coordinate a large number of virulence
determinants including cell-wall-associated proteins and
exoproteins. (Cheung et al., 2004). The sar locus encodes a
DNA-binding protein SarA; a 14.7 kDa winged helix turn helix
transcriptional activator and known to up-regulate the agr based
quorum sensing system to elicit the exoprotein level (Cheung
et al., 2004; Beenken et al., 2010). Simultaneously, the SarA
indirect role on down-regulation of various other regulatory
loci such as rot, sarS, sarV, sarT are well documented (Arya and
Princy, 2013a). The DNA binding studies have revealed that the
SarA binds to the intergenic region of P2 and P3 promoters of
the agr locus and modulates the downstream genes such as hla
and spa that encodes alpha hemolysin and protease respectively
(Chien et al., 1999). But, the stable expression of both the
genes in agr null strains strongly suggest the role of SarA on
modulating its target gene expression either in direct or indirect
manner (Cheung et al., 2008). Furthermore, SarA is also involved
in the agr-independent expression of several other virulence
genes including fnbA (fibronectin binding protein A), TSS
(toxic shock syndrome) and icaRA (coagulase)and bap (biofilm
associated proteins). Trotonda et al. (2005), Roberts et al. (2006),
Andrey (2010) and Arciola et al. (2012). Existing antibacterial
treatments for prosthetic vascular graft associated infections are
inadequate due to the emergence of multi-drug resistance thus
emphasing the need for combinatorial and higher dose therapy
(Legout et al., 2014). So, there is a strong necessity for the novel
therapeutic compounds to overcome antimicrobial resistance. In
the current era few selective anti-virulent candidates have been
revealed as a potent inhibitor of S. aureus agr based infections
(Kiran et al., 2008; Sully et al., 2014). Targeting the SarA-DNA
interaction has resulted in the identification of the first novel
and extremely selective inhibitor that can efficiently suppress
the staphylococcal infections. Hence, in an effort to develop an
alternative treatment, several drug like molecules were designed
and evaluated to assess their potentiality to overcome the
pathogen responses to host tissues. Our study also demonstrates
the advancement of research in this direction of exploiting
the quorum regulator and score a novel potent SarA selective
therapeutic candidate to dodge the S. aureus pathogenesis.
Material and Methods
Bacterial Isolates and Growth Conditions
S. aureus (105 strains) were isolated from rejected vascular
graft (KAP Viswanatham Government Medical College,
Trichy, India) and analyzed for the expression of virulence
genes including antibiotic resistance, hemolysin production,
biofilm formation and protease production. The strains that
exhibited a higher degree of expression on those virulence
factors were used for the drug efficacy analysis. To analyze the
antimicrobial resistance pattern, the antibiotics such as penicillin,
azithromycin, vancomycin, cefazolin, clindamycin, cloxacillin,
erythromycin and teicoplanin were used in the study. The
ATCC 25923 and mutant strains [Newman1agr::tetM,Newman
sarA::Tn917LTV1, Newman 1agr::tetM, sarA::Tn917LTV1]
were grown aerobically at 37◦C in tryptic soy broth (HiMedia,
laboratories, India) overnight and the cultures were stored for
further use (Table 1).
For broth culture, the S. aureus strains were grown in tryptic
soy broth and the culture was incubated at 37◦C with constant
shaking at 200 rpm and the cells were harvested at exponential
phase. The growth rate was measured spectrophotometrically at
600 nm (OD600). Wolz et al. (2000), Boles et al. (2010), Chen et al.
(2011), Coraça-Huber et al. (2012).
Computational Methods
Structure assisted drug designing and molecular docking was
used to design several drugs like molecules against the SarA DNA
binding sites. Briefly, the 3-dimensional X-ray crystal structure
of SarA was retrieved from the protein data bank [Accession
ID: 2FRH] and further processed. The three amino acids D88,
E89, and R90 responsible for conferring its binding to DNA
(DNA binding domain) was selected as the target residues for
the molecular docking analysis and the interactions of SarA with
ligands formed the basis for design and scoring. Liu et al. (2006)
and Arya and Princy (2013b).
The leads were subjected to the refinement as it improved
their specificity, physiochemical properties including absorption,
distribution, metabolism, excretion (ADME), and toxicity profile.
Synthesis of SarA Based Biofilm Inhibitor
(SarABI)
The SarABI was synthesized by the condensation of commercially
available 2,4 difluorobenzyl bromide and 4-aminocyclohexanol
(Sigma-Aldrich) (Scheme-1).
The condensation reaction was carried out on an ice bath in the
presence of NaOH with constant stirring for 3 h. The reaction
mixture was extracted with ethyl acetate. The pooled organic
layers were washed successively and then washed with 10%
HCl, 10% potassium carbonate and with brine, and dried over
anhydrous magnesium sulfate. The formation of the SarABI was
confirmed with proton and carbon nuclear magnetic resonance
spectra followed by the gas chromatography mass spectra. The
presence of hydroxyl group was confirmed by D2O exchange and
Fourier transforms infrared spectroscopy (FT-IR using KBr).
in-vitro Analysis of SarABI Efficacy
Minimum Biofilm Inhibitory Concentration (MBIC)
A biofilm susceptibility assay (MBIC) was used to quantify the
anti-biofilm activity of SarABI. S. aureus strains were grown
overnight in TSB, diluted 1:100 in fresh TSB medium and
grown to early exponential phase (OD595 = 0.2). Then 100µl
(approximately 2 × 107 bacteria) of the culture were applied
to sterile polystyrene 96-well plates along with 2-fold dilution
series of SarABI and untreated culture was used as a control.
The assay plates were incubated for 18 h at 37◦C and then
non-adherent cells were removed on repeating the washing
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TABLE 1 | Bacterial strains used in this study.
Strain Relevant genotype or phenotype Reference/source
ATCC 25923 clinical isolate ATCC
ALC 355 Newman 1agr::tetM 11
ALC 637 Newman, sarA::Tn917LTV1 11
ALC 638 Newman 1agr::tetM,sarA::Tn917LTV1 11
QSLSA1051, QSLSA1052, QSLSA762, QSLSA764,
QSLSA782, QSLSA785, QSLSA1061, QSLSA 1068,
QSLSA 1149, QSLSA95, QSLSA1097
Wild type laboratory strain This work
step with phosphate buffered saline. The cells adhered to the
polystyrene plates were stained with 50µl of 0.06% crystal violet
and the optical density was read at 600 nm to quantify the extent
of biofilm formation. The concentration of the SarABI was used
in a serial 2-fold dilution that could inhibit the biofilm formation
by 50% (MBIC50) and 90% (MBIC90) compared to the untreated
control (Opperman et al., 2012). The calculated MBIC50 and
MBIC90 data were used in all the subsequent experiments to
analyze the efficacy of SarABI.
Antimicrobial Activity Assay
S. aureus strains were grown overnight in TSB and diluted 1:100
in fresh TSB to reach early exponential phase of growth. Then
100µl of this culture was applied to sterile 96-well polystyrene
plates without or with the effective concentrations of SarABI
(MBIC50 and MBIC90) was observed at 200µg/ml and 1mg/ml
respectively). Cultures were grown without shaking for 24 h at
37◦C and the optical density wasmeasured at 595 nm, then 100µl
of culture were plated on to TSA for determining the colony
forming units (Kiran et al., 2008).
Hemolysin Production
Hemolytic activities of the SarABI were determined using rabbit
erythrocytes. S. aureus were cultured overnight and diluted
OD600 = 0.1 in 20ml of fresh TSB and incubated for 3 h at
37◦C till an approximate OD600of 0.6. The cells were collected by
centrifugation at 10,000 × g for 10min at 4◦C and re-suspended
in 20ml of phosphate buffer saline (PBS). The 2% erythrocytes
were prepared on centrifuging 1ml of fresh de-fibrinated blood
(1620 × g, 10min) and the pelleted cells were re-suspended in
1ml sterile PBS. The cells were repeatedly washed with PBS and
re-suspended in 0.75ml PBS and 2% erythrocyte suspension.
Further 100µl of the bacterial culture with or without SarABI
(MBIC50 and MBIC90) as independent experiments were mixed
with 900µl of 2% red blood cells and incubated at 37◦C for
3 h. The aliquot were centrifuged and the percent hemolysis was
measured at an optical density of 540 nm (De Latour et al., 2010;
Dean et al., 2011).
Bacterial Cell Adherence
Labeling S. aureus with fluorescein isothiocyanate (FITC)
The multi-drug resistant clinical isolates and reference strain
were grown to early exponential phase. Cell pellets were
re-suspended in PBS and sodium bicarbonate buffer with
Fluorescein isothiocyanate (FITC) (1.0mg/ml; Sigma Aldrich).
The cells were incubated overnight at 4◦C with gentle stirring
and further washed with sodium bicarbonate buffer (Hochbaum
et al., 2011).
Cell adherence
The FITC labeled S. aureus cells were diluted 1:100 in PBS.
100µl of cells (2 × 107) were applied to sterile cover slides in
12 well polystyrene plates with or without SarABI (at its effective
concentration) and incubated for 30min at 37◦C. Thereafter
cover slides were repeatedly washed with PBS and fluorescence
determined at 485/530 nm (Zeiss AxioA1, Progress C5) (Bose
et al., 2012).
Bacterial attachment to polystyrene in vitro
Briefly S. aureus strains were grown to the early exponential
phase with OD595nm = 0.2 (contains 2 × 10
7 bacteria). To
analyze the cell attachment, 100µl of the bacterial culture was
taken in sterile 96 wells polystyrene plate with or without SarABI
(at its effective concentration). Cells were grown for 3 h at 37◦C
and the unbound cells were removed on repeated washing with
phosphate-buffered saline. The cells were air-dried and fixed with
100% ethanol and stained for 2min with 0.4% gentian violet
where the excess stains were removed on washing with PBS. A
100µl of 1% sodium dodecyl sulfate (SDS) was added to each well
to solubilize the stained cells. The optical density was measured
at OD595 in 96 well plate reader (Biorad Plate Reader, Bio-Rad,
Hercules, CA, USA) (Gov et al., 2001; Krut et al., 2003).
Confocal laser scanning microscope (CLSM) of static
biofilm
Static biofilms were grown in a 8-well cover glass plates (Nunc,
Wiesbaden, Germany) was subjected to analysis using confocal
microscope (Olympus America, Inc., Melville, NY) after gentle
washing and staining with fluorescent isothiocyanate (0.1%
in PBS) for 15min. The cells were washed twice in PBS
and the developed biofilms were analyzed at excitation and
emission wavelength 488 and 520 nm respectively by adjustable
spectrum slit (Periasamy et al., 2012). Further the COMSTAT
(Biofilm Image Processing Tool) was used to analyze the biofilm
thickness, roughness, bio-volume and minimum colony size at
the substratum.
Quantitative Real Time-PCR (qRT-PCR)
The total RNA was isolated from the SarABI (at its effective
concentration) treated and untreated cells using guanidinium
thiocyanate (Chomczynski and Sacchi, 2006).
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The single step qPCR experiment was performed in a real-
time cycler using SYBR Green method (Genotypic technology,
India). The fnbA, hld and RNAIII expression patterns were





5′ (reverse). Relative levels (RL; %) of fnbA, hld and RNAIII
transcripts were calculated using comparative Ct method and
normalized to those of arc (carbamate kinase- house-keeping
gene) transcript expression (Wolz et al., 2000).
Rat Graft in-vivo Infection
The animal experiments were performed according to the
experimental practices and standards developed by the animal
welfare also with the prior approval from the Institutional
Animal Ethics Committee (IAEC). Adult male Wistar rats (8–
12 weeks) were used in the study, as it includes two series
consisting of seven groups. Sterile collagen sealed double velour
knitted polyethylene terephthalate (PET; Dacron) graft was used
as the medical device in these experiments. For the animal
experiments, the control group (disease control, DC) implanted
with the unsoaked grafts and the experimental groups (infected
either with the clinical isolates or the mutant strains) were
implanted with SarABI soaked grafts as independent experiments
were maintained. All rats were subjected to a minor surgery
to make a subcutaneous pocket on each side of the median
line by a 1.5 cm incision. All grafts were explanted after 15
days of implantation and biofilm formation was analyzed by
determining the colony forming units. Various biochemical
parameters such as albumin, ALT (alanine aminotransferase),
ALP (alkaline phosphatase), AST (aspartate aminotransferase),
direct bilirubin, total bilirubin, total protein, creatinine and urea
were determined to analyse the toxicity of drug (Wang et al.,
2011).
Histophalogy and Bacterial Count
Wistar rats were sacrificed after 15 days where the tissues
from the graft site, liver, kidney, spleen, PET grafts and blood
samples were collected. The tissue samples were further analyzed
histopathlogically as well as processed for bacterial count. For
histopathogical analysis, tissues were fixed in 10% formalin
and sliced into a thickness of 2.1mm. The tissues were then
dehydrated with alcohol of graded concentrations. Subsequently
the samples were cut on a microtome to 5µm and stained with
haematoxylin-eosin. The stained samples were examined under
a light microscope; and photomicrographs of the samples were
recorded (Bellows et al., 2011).
For bacterial count from various tissues, the samples were
homogenized in PBS and serially diluted samples were then
plated on 5% sheep blood agar plates. Similarly, 100µl of blood
samples were also cultured on blood agar plates. The collected
PET grafts were sonicated in PBS so as to detach the adherent
bacterial cells and the samples were cultured on blood agar plates
to count bacterial cells (Aboshady et al., 2012).
Cytotoxicity Assay
The chemo-sensitivity of HEp-2 cells were determined using [3-
(4, 5-dimethyl thiazol-2yl)-2, 5-diphenyl tetrazolium bromide]
(MTT) standard assay. Briefly HEp-2 cell line (2 × 106cells/ml)
was seeded in 96-well plate. The adherent cells were grown
to confluences for 24 h to allow cell attachment. The effective
concentration of SarABI was added to each well and incubated
for 72 h. The MTT solution was added and the cell viability was
measured at 540 nm (George et al., 2012).
Adherence Assay to HEp-2 Cell
Clinical isolates and mutant strains of S. aureus cells were
labeled with fluorescein isothiocyanate (FITC) as described
earlier (Balaban et al., 2003). To assess S. aureus adherence
to HEp-2 human epithelial cells culture was applied to 8-
well cover glass plates and allowed to grow at 37◦C in a 5%
CO2 incubator in bicarbonate-buffered dulbecco modified eagle
medium (DMEM) (Sigma-Aldrich, USA) supplemented with
5% fetal calf serum (FCS) (Himedia. laboratories, India) to
reach confluency (2 × 105 cells/ml). FITC-labeled S. aureus
(2 × 106 cells/well in 90µL PBS) were added to the confluent
layer of HEp-2 cell line with or without SarABI at its effective
concentration. S. aureus and HEp-2 cells were incubated for
30min at 37◦C and further washed with PBS and the intensity
of fluorescence was determined at 485/530 nm under the
CLSM.
Statistical Analysis
Statistical analysis was carried out using graph pad prism
software (version 4.03). One-Way ANOVAwas used, followed by
Newman-Keuls multiple comparison test using GraphPad prism
program version 6.0 (Graph Pad Software Inc., San Diego, CA).
The minimum level of significance was set at P = 0.001. All
assays were conducted in triplicates and statistical analysis was
done.
Results
Design and Synthesis of Novel SarA Based
Inhibitor (SarABI)
A pool of several hits was generated that could favorably
interact to the DNA binding site of SarA using the de novo
evolution mode of the program (Liu et al., 2006). The top-hit
ligand was selected according to their relative energies, docking
score, molecular and pharmacokinetic properties. The docking
analysis revealed that the SarABI forms hydrogen bond with
glutamic acid and arginine at 88 and 89 positions respectively.
The reaction sequence leading to the formation of desired
SarABI as outlined in scheme-1 yielded 72% of the compound.
The presence of the hydroxyl group at characteristic position
and number of protons (Figure S1) and carbons, the presence
of benzene and cyclohexanol ring was confirmed (Figure S2).
The D2O exchange and FTIR spectra confirmed the presence
of amide and hydroxyl moiety in the SarABI (Figure S3). A
corresponding molecular weight of 241 was confirmed with the
GC-MS (Figure S4).
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Determine SarABI Minimum Biofilm Inhibitory
Concentration (MBIC)
The concentration of a drug required to either reduce 50% of
biofilm deposition (MBIC50) or inhibit the biofilm formation up
to 90% (MBIC90) was used as a standard for the assessment of
FIGURE 1 | Determination of minimum biofilm inhibitory concentration
(MBIC). Cultures treated with various concentrations of SarABI were analyzed
after 24 h comparing the effects of expressing a biofilm in S. aureus ATCC
25923. The static biofilm assay was performed with TSB medium, dotted line
shown the difference between control and experimental groups. Statistical
analysis was performed using the Two-Way ANOVA and Values of P < 0.001
were considered significant. Asterisk (*) indicates non detectable expression of
biofilm.
SarABI sensitivities for multi-drug resistantS. aureus. The effect
of SarABI on the biofilm formation at various concentrations
were analyzed and it was observed that the reduction was
prominent in a concentration-dependent manner. The SarABI
exhibited an inhibitory effect on the development of S. aureus
biofilm with MBIC50 of 200µg/ml. No significant biofilm
formation was observed in any of the clinical isolates when
incubated with SarABI at a concentration of 1mg/ml of the
growth medium prior to inoculation (Figure 1).
SarABI Efficiently Act on Bacterial Growth and
Hemolysin Production
The drug, SarABI was designed to repress the expression of
virulence genes, including biofilm formation and hence, did
not exert any kind of selective pressure on bacteria to become
resistant. The results obtained from colony forming units clearly
indicated that SarABI did not exhibit antibacterial activity against
S. aureus. The in-vitro antibacterial activity of SarABI with
reference to its optimal concentration of MBIC50 (200µg/ml)
and MBIC90 (1mg/ml) were tested on multiple drug resistant S.
aureus strains. The study clearly indicated that the SarABI did not
exhibit antibacterial activity against these strains up to the tested
concentration of 1mg/ml (Figure 2).
As shown in Figure 3, hemolysin activity was significantly
decreased in the clinical isolates and agr mutant strain (Newman
1agr::tetM) when treated with SarABI but considerably
increased in the sarA mutant (Newman sarA::Tn917LTV1)
as compared to the control. These results are consistent with
the data that the SarABI shows SarA selective suppression of
the biofilm formation. The hemolytic activity of the clinical
isolates and mutant strains were also tested and it was found
that 200µg/ml of SarABI had reduced the hemolytic activity to
50% and >100% was observed as the drug (SarABI) dose was
increased to 1mg/ml.
FIGURE 2 | Colony forming unit assays of clinical isolates and mutant
strains of S. aureus. The strains were incubated for 24 h (2× 107 cfu/ml)
with the addition of 200µg/ml and 1mg/ml SarABI in tryptic soy agar plates
which does not affect the viability of clinical isolates compared to control. A
similar effect was observed in mutant laboratory strains (ALC355, ALC637,
ALC638), dotted line shown the difference between control and experimental
groups. Statistical analysis was performed using the Two-Way ANOVA and
Values of P < 0.001 were considered significant.
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FIGURE 3 | Synergistic in comparison to direct lysis of rabbit
blood erythrocytes by S. aureus with SarABI. Culture supernatants
were grown in presence (200µg/ml and 1mg/ml, respectively) or
absence of SarABI, culture filtered and incubated with a 2% solution of
defibrinated rabbit blood for 30min at 37◦C. Hemolysis was measured
by determining OD540nm using spectrophotometer and % lysis
calculated from lysed erythrocyte standards, dotted line shown the
difference between control and experimental groups. Statistical analysis
was performed using the Two-Way ANOVA and Values of P < 0.001
were considered significant. SarABI significantly decreases the
expression of hemolysin in all experimental groups. Asterisk (*) indicates
no weak expression of hemolysin.
Small Molecule SarABI, Attenuate the Bacterial
Cell Adherence
The study was performed to analyze whether the results
from extracellular protein secretion and biofilm formation
have precisely mirrored the bacterial attachment. So, the S.
aureus strains listed in Table 1 were compared for their cell
adherence capacity on the solid surface. The sarA mutant
(Newman sarA::Tn917LTV1) and agr sarA double mutant
(Newman 1agr::tetM, sarA::Tn917LTV1) strains were observed
to be weak biofilm produces and naturally lost their ability to
adhere to the solid (polystyrene plate) surface. As expected,
the SarABI treatment caused a remarkably reduced adherence
in all clinical strains along with the agr mutant under static
conditions subjected to an incubation for 30min (Figure 4).
The data clearly implies the major role of SarA played a
major role in the activation of key S. aureus surface associated
genes.
SarABI Significantly Inhibit Biofilm Formation
The efficacy of SarABI on biofilm inhibition was studied in
situ over time for all the strains using the confocal laser
scanning microscopy (CLSM). As shown in Figure 5, the real
time measurement of biofilm thickness using time lapse CLSM
imaging revealed that untreated clinical isolate, SA1061 has
shown a significantly higher biofilm formation with a thickness
up to 11µm in elevation over the surface. On the other hand,
the SarABI treatment affected the biofilm forming ability of
the S. aureus clinical isolates, ATCC 25923 and the agr mutant
strains SA1061 strain displayed the highest level of total biomass
(11µm3/µm2) andmaximum thickness (>10µm). In contrast, a
sharp reduction in biovolume ranging from 0.2 to 1.9µm3/µm2
and thickness (0.2–1.0µm) was observed in all the treated
strains. Similarly, a fivefold reduction in the roughness coefficient
was observed in SarABI treated strains (∼0.3µm3/µm2) than
that of control (1.4µm3/µm2). Minimum colony size at the
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FIGURE 4 | Effective concentration of SarABI reduced for the
adherence of Staphylococcus aureus. (A) FITC labeled ATCC 25923
cells (109 CFU) were applied to glass slide with 100µl of PBS, (B) clinical
isolate SA1061, (C) ALC637 (sarA::Tn917LTV1), (D) ALC355 (1agr::tetM),
(E) ALC638 (1agr::tetM sarA::Tn917LTV1) effective concentration of SarABI
were used for the adherence. Cells were incubated for 24 h at 37◦C,
unbound cells were removed by PBS washing and adherent cells observed
under the fluorescent microscopy 5x.
substratum for treated S. aureus strains ranged from 50 to 75µm2
as compared to that of control where a considerable larger
colony size (6000µm2) was observed. Prominently, these results
emphasize that the SarA was not a sole regulator to control the
biofilm formation as earlier presented but also epitomized as a
crucial molecular factors contributing to biofilm structuring in S.
aureus.
SarABI targets SarA Based Major Virulence
Genes Expression
The SarABI, an inhibitor suppressed the transcriptional activator
SarA and negatively controlled it to down-regulate its target
genes that influences the adhesion molecules biosynthesis as
well as certain toxin production. Hence, inactivation of temporal
expression of these genes should invariably affect the expression
of RNAIII, δ-hemolysin (hld) and fibronectin binding protein
A (fnbA). To determine the fact whether the SarA selective
inhibitor (SarABI) has down-regulated the phenotype, biofilm
and other virulence factors, the quantitative real time PCR
(qPCR) analysis of their transcript levels were also done. As
shown in Figure 6, the treatment of highly virulent clinical
isolate, SA1061 with SarABI (TSA) at a concentration of 1mg/ml
greatly reduces the expression of fnbA, RNAIII, and hld as
compared to the untreated (CSA) strain. The expression of
house-keeping genes, arc and 16s rRNA were also quantified to
analyze the effect of SarABI on the survival of S. aureus. No
significant changes in the expression of those reference genes
were observed in both TSA and CSA. Hence the results were
consistent to show the SarABI, a well-characterized SarA based
inhibitor.
SarABI Treatment in-vivo Diminishes Vascular
Graft Infection
The SarA selective inhibitor, SarABI has proven to show anti-
adherence effect to potentiate its role to overcome the device-
associated infections in-vivo. Graft presoaked with 200µg/ml
and 1mg/ml showed no sign of infection even though the animals
were challenged with a high bacterial load of 2 × 107 cfu and
were analyzed by the colony forming units on blood agar plates
(Figure 7).
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FIGURE 5 | (A) The effect of SarABI on S. aureus attachment to polystyrene In
vitro: Cell attachment compared with the clinical isolates and the mutant
backgrounds ALC355 (1agr::tetM), ALC637 (1sarA::Tn917LTV1) single
mutants, and the ALC638 (1agr::tetM,1sar::Tn917LTV1 double mutants)
treated with SarABI. S. aureus cultures grown in 96-well microtiter plates were
pretreated with SarABI (200µg/ml and 1mg/ml respectively) and incubated for
24 h. Values show mean numbers of biofilm formation/well, and error bars
indicate range, dotted line shown the difference between control and
experimental groups. Statistical analysis was performed using the Two-Way
ANOVA and values of P < 0.001 were considered significant. SarABI
significantly decreases the expression of biofilm in all experimental groups.
Asterisk (*) indicates no detectable expression of biofilm. (B) Quantitative
analysis of biofilm development on coverslips by S. aureus strains treated with
SarABI using CLSM shows biomass, roughness coefficient, thickness and
minimal colony at the surface and biofilm production by S. aureus as assessed
by three dimensional images compared with untreated biofilms. Statistical
analysis was performed using the Two-Way ANOVA and values of P < 0.001
were considered significant. Asterisk (*) indicates drastically decline fluorescent
intensity.
Biochemical analysis of the serum sample was performed to
evaluate the SarABI toxicity effect over the function of the renal
and the hepatitis systems. The data showed that the SarABI
at its effective concentrations (200µg/ml and 1mg/ml) inhibits
the S. aureus biofilm and virulence but did not affect the
normal function of the host cells in comparison with the control
(untreated groups) (data not shown). Similarly, histopathological
studies of SarABI effect on wistar rats demonstrated that even
administration of higher dosage of this drug does not cause any
FIGURE 6 | The validation of virulence gene expression level using
quantitative RT-PCR. S. aureus were grown overnight at 37◦C with (TSA,
treated S. auerus) or without (CSA, control S. aureus) treated of 1mg/ml
SarABI in tryptic soy broth. Expression pattern of the fnbA, hld, and RNAIII
were diminished in cells treated with SarABI in comparison to without treated.
Statistical analysis was performed using the Two-Way ANOVA and values of
P < 0.001 were considered significant. Asterisk (*) indicates significantly low
expression of genes.
FIGURE 7 | Quantitative microbiological evaluation experiments shows
SarABI reduced in-vivo infection. Bacteria (2× 107CFUs) were incubated
with SarABI for challenge the animals. After 14 day incubation, the graft was
removed, and the number of bacteria were determined on blood agar plates.
The graph depicts group-I (control), group-II (DC, Diseased control infected
with ATCC 25923), group-III (CI, S. aureus clinical isolate with SarABI),
group-IV (AT, ATCC 25923 with SarABI), group-V (AG, agr::tetM with SarABI),
group-VI (SA, sar::Tn917LTV1 with SarABI) and group-VII (DM, agr::tetM,
sar::Tn917LTV1 with SarABI). The low and effective doses of SarABI were
used for studied, dotted line shown the difference between control and
experimental groups. Statistical analysis was performed using the One-Way
ANOVA and values of P < 0.001 were considered significant. Asterisk (*)
indicates no detectable bacteria, suggesting <10 CFUs/ml.
change in the cellular integration of the liver, kidney, spleen along
with the epithelial cells from the graft site while the lesion was
observed in adjacent to the epithelial cells from the graft site of
the untreated group. All the organs from the drug treated group
were found within the histological limits as compared with the
control group (Figure 8).
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FIGURE 8 | Hematoxylene and eosin stained sections of tissues
from implant site. Skin ulcer and necrotic debris was observed in
disease control group. Disease control group (B, I) also exhibits a
marked tissue reaction with predominant macrophages, fibroblasts,
lymphocytes and neutrophils along with collagen deposition. A fibrous
capsule and granulation tissue formation with angiogenesis was
predominantly present in the sections. (I,II) represents the 200µg/ml
and 1mg/ml SarABI coated vascular grafts experimental groups
respectively. Representative samples from different groups treated with
SarABI do not show any significant difference from saline control (A,
H), DC (B, I), CI (C, J), AT (D, K), ALC355 (E, L), ALC637 (F, M) and
ALC638 (G, N).
Cell Proliferation Not Affected by SarABI
The cytotoxic effect of the effective concentration of SarABI
(200µg/ml and 1 mg/m) on the cell viability were evaluated. A
compound usually is considered to have in vitro cytotoxic effect
if the particular concentration of drug caused a 50% cell death. In
this study, the cell viability was found to be higher than 95% in all
the drug doses and hence, the SarABI showed no cytotoxic effect.
SarABI Reduces Adherence of S. aureus on
Hep-2 Cells
To investigate the role of SarABI on preventing the S. aureus from
colonizing the confluent layer of Hep-2 cells, a control (ATCC
25923), clinical isolate and three mutant strains were subjected to
CLSM analysis and further the influence of drug (SarABI) over
its adherence influenced by various parameters (function of bio
volume, roughness coefficient, colony size and mean thickness)
were characterized using COMSTAT. The data critically revealed
a differential pattern of adherence between the treated and
untreated groups to Hep-2 cells under the same conditions other
than the mutant strains (Newman sarA::Tn917LTV1, Newman
1agr::tetM and sarA::Tn917LTV)., As shown in the Figure 9, the
untreated control produces a biovolume of 11µm3/µm2 while
the SarABI treatment at a concentration of 1mg/ml significantly
reduced the biovolume ranging from 0 to 2µm3/µm2. The
SarABI treatment also reduced the biovolume in the strain,
ALC355 while ALC638 did not exhibit any biofilm formation.
The minimum colony size at substratum analysis showed that
the SarABI treatment reduced the colony size from 6000µm2
(untreated) to 50µm2. The roughness coefficient was also
reduced from 1.4 to nearly 0.3 for all the clinical isolates when
treated with SarABI. A higher biofilm was measured in the
control and exhibited 11µm thickness in comparison with the
treated isolates and the thickness of the biofilm ranged from 0
to 1µm. Also the influence of the drug (SarABI) to inhibit the
S. aureus adherence to the host cell is consistently similar to the
effect achieved from our previous adherence assay carried out on
the glass surface.
Discussion
The study demonstrates a unique approach to inhibit
the staphylococcal virulence and pathogenesis via., inhibiting
the SarA based quorum sensing. The method demonstrated
the inhibition of virulence gene expression rather than killing
the bacteria. In our previous study, we have used denovo
computer-aided discovery of novel SarA selective inhibitors
against the target, SarA (PDB ID: 2FRH) (Arya and Princy,
2013b). The SarABI has shown better interaction with the
protein, SarA by H-bond acceptor and donor, presence of
aromatic rings, functional groups and hydrophobic sites. These
interactions provided the SarA-SarABI to form a stable complex
as it laid a key role to negatively regulate the SarA interaction
to its target promoter regions. The complex was also stabilized
by hydrogen bond interactions with the Asp and Glu residues
at 88 and 89th position in SarA and ensures to bind to the
hydrophobic clamp. Also the presence of fluorine, hydroxyl and
amine group might have an imperative role in the inhibition
activity.
The compound, SarABI was further tested for its potency
at inhibiting biofilm formation against all clinical isolates
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FIGURE 9 | Effect of SarABI on adherence of S. aureus to HEp-2
cell lines. The graph depicts Control (with normal saline), DC (Diseased
control contaminated with ATCC 25923), CI (S. aureus clinical isolate with
SarABI), AT (ATCC 25923 with SarABI), ALC355 (agr::tetM with SarABI),
ALC637 (sar::Tn917LTV1 with SarABI) and ALC638 (agr::tetM,
sar::Tn917LTV1 with SarABI). The effective concentration of SarABI
synergistically diminished the adherence of S. aureus to HEp-2 cell lines.
(A) Data revealed the significantly reduce in biomass, roughness coefficient
thickness and colony at substrate compared with untreated samples. (B)
Three-dimensional reconstructed renderings of the S. aureus adherence to
HEp-2 cells on coverslip. The effective doses of SarABI were used for
studied. Statistical analysis was performed using the Two-Way ANOVA
and values of P < 0.001 were considered significant. Asterisk (*) indicates
significant result.
and isogenic (agr and sarA) mutant strains. The agr null
strain had shown a significant higher expression of biofilm
while the expression was reduced when treated with SarABI.
The result suggested that the SarABI affects the biofilm on
negatively regulating SarA-specific interaction of SarABI to
downregulate SarA targeted genes expression that establishes
biofilm. Furthermore, the cell adherence assay also revealed that
the untreated clinical isolates, agr null strain and the reference
strain, ATCC 25923 exhibited a higher adherence on the glass
surface while the SarABI treatment inhibited the bacterial cells
attachment. The sarA and agr sarA double mutant strains
(Newman 1agr::tetM, sarA::Tn917LTV1) either treated with
SarABI or untreated did not induce biofilm formation. These
results confirmed that SarABI acts via opposing the effects of
SarA and most likely inhibited the binding of SarA to the DNA
(Arya and Princy, 2013b) hence affecting the quorum sensing
Frontiers in Microbiology | www.frontiersin.org 10 May 2015 | Volume 6 | Article 416
Arya et al. Antivirulent drug against Staphylococcus aureus
processes. Thus, the SarA selective inhibitor, SarABI was found to
be very effective in suppression of the process of cell attachment,
proliferation and invasion.
The biofilm formation in S. aureus is a multistep process that
commences with the cell attachment and then the expression
of genes responsible for extracellular toxins production (Lister
and Horswill, 2014). An array of hemolytic proteins is
frequently isolated from S. aureus and is among the most
significant staphylococcal toxins. The hemolysins and associated
proteins are pore-forming staphylococcal virulence factors that
significantly contribute in bacterial infections (Tavares et al.,
2014). A concentration-dependent inhibition of hemolytic
activity was observed when the clinical isolates were treated with
SarABI.
As the effective concentration of 200µg/ml (MBIC50) and
high dose of 1mg/ml (MBIC90) of SarABI were found to
inhibit the biofilm formation as observed in the MBIC assay,
we furthermore sought to define and analyze the impact of the
drug on the biofilm formation using fluorescence labeling of
the biofilm. There was substantial reduction in the degree and
kinetics of biofilm formation with the strains treated with SarABI.
In static biofilms, biovolume, roughness coefficient, colony size
andmean thickness values were considerably higher in the ATCC
25923, agr mutant, Newman 1agr::tetM and all clinical isolates
compared with those values of the treated strains.
The expression of the various genes including RNAIII, fnbA
and hld plays an imperative role in staphylococcal pathogenesis
including biofilm formation, proliferation and evasion (Beenken
et al., 2010). The transcription of RNAIII was greatly reduced
in the S. aureus culture supplemented with SarABI and hence
changed the temporal expression of various virulence factors.
The lack of adherence and biofilm formation in sarA mutant
(Newman sarA::Tn917LTV1) and SarABI treated clinical isolates
also suggested that the activation of fibronectin-binding proteins
promotes their adherence to the surface or host epithelial
cells is under the direct control of SarA. This was remarkably
substantiated by the RT-qPCR data where the down-regulation
of all those genes was detected during exponential phase after
treatment, demonstrating SarABI interference with SarA to show
its response to its target genes at the transcriptional level. As
expected, the expressions of all three transcripts were correlated
with the decreased biofilm formation and hemolysin activity of
all clinical strains.
The cytotoxicity of the SarABI was also evaluated and
results demonstrated that the SarABI did not show cytotoxic
effect to HepG-2 cell line even at its higher concentrations.
Remarkably, SarABI a novel drug to show its effect on inhibiting
a quorum regulator, SarA and further to downregulate several
gene expression that establishes biofilm and virulence without
affecting the cell growth. So, this approach would block an
independent pathway other than the vital pathways responsible
for their life cycle. The approach toward finding an “anti-
virulent” drug in the control of pathogenic bacteria imposes a
control over its pathogenic phenotypes rather than developing
selective pressure and drug resistance.
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Figure S1 | Chemical characterization of the Trans-4-[(2, 4-difluorobenzyl)
amino]cyclohexanol (SarABI) after an 8h reaction with catalyst NaOH. The
distribution of characteristic aromatic and aliphatic protons according to their
occurrence in those regions was confirmed with proton NMR. The hump region
denotes the presence of NH group.
Figure S2 | 13C NMR Spectra of SarABI. The carbon NMR spectrum was used
to confirm the two benzene rings along with the diamine aliphatic region according
to their prediction space in the spectra.
Figure S3 | Characteristic FTIR absorbencies of the SarABI.Major vibrational
bands interpreted to be due to: H-bonded OH-stretching (3415.42 cm−1).
Figure S4 | Mass Spectroscopy Determination of SarABI was analyzed by
GC/MS in CI mode using Helium flow for ionization to determine
molecular weights. The sample was pyrolysed at 290◦C, and the resulting
vapor was injected into gas chromatograph mass spectrometer (GC–MS). The
different gaseous products were separated by the GC, and analyzed by MS in the
GC column outlet and identify the products by their mass spectrum.
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